0.00Open0.20Pre Close0 Volume405 Open Interest8.00Strike Price0.00Turnover167.96%IV27.58%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier11DDays to Expiry0.20Extrinsic Value100Contract SizeAmericanOptions Type-0.1120Delta0.0590Gamma53.85Leverage Ratio-0.0271Theta-0.0004Rho-6.03Eff Leverage0.0037Vega
Omeros Stock Discussion
how long will the hold off volume before reaching above 30
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
Omeros (OMER) announced successful results from its narsoplimab pivotal trial for treating transplant-associated thrombotic microangiopathy (TA-TMA). The primary statistical analysis showed that patients treated with narsoplimab had an over 3-fold reduction in mortality risk (hazard ratio = 0.32) compared to untreated p...
No comment yet